2007
Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Molecular Cancer Therapeutics 2007, 6: 2652-2663. PMID: 17913856, DOI: 10.1158/1535-7163.mct-06-0759.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsAntineoplastic AgentsBlotting, WesternCell ProliferationEpidermal Growth FactorErbB ReceptorsGefitinibGene DosageHumansLung NeoplasmsMaleMiceMice, NudePhosphorylationPurinesQuinazolinesReverse Transcriptase Polymerase Chain ReactionTransforming Growth Factor alphaXenograft Model Antitumor AssaysConceptsTumor-associated endothelial cellsEpidermal growth factor receptorTreatment of miceLung cancerEpidermal growth factorNCI-H441Endothelial cellsLung tumorsLigand expressionNon-small cell lung cancerExpression of EGFTumor cellsEGFR tyrosine kinase inhibitorsEGFR tyrosine kinase inhibitor gefitinibGrowth factorReceptor tyrosine kinase inhibitionTyrosine kinase inhibitor gefitinibLymph node metastasisCell lung cancerEGF receptor tyrosine kinase inhibitionLungs of miceHuman lung cancer cellsHuman lung cancerPrimary tumor growthTyrosine kinase inhibitorsTargeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Molecular Cancer Therapeutics 2007, 6: 471-483. PMID: 17308046, DOI: 10.1158/1535-7163.mct-06-0416.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAngiogenesis InhibitorsAnimalsApoptosisBlotting, WesternCarcinoma, Squamous CellCell Line, TumorCell ProliferationEndothelium, VascularErbB ReceptorsFlow CytometryHumansLung NeoplasmsMaleMiceMice, Inbred BALB CMice, Inbred CBANeovascularization, PathologicPhosphorylationPiperidinesProto-Oncogene Proteins c-aktQuinazolinesSignal TransductionVascular Endothelial Growth Factor Receptor-2Xenograft Model Antitumor AssaysConceptsVascular endothelial growth factorVEGF receptor 2EGF receptorEpidermal growth factorLung cancerHuman lung cancerEndothelial growth factorGrowth factorMitogen-activated protein kinaseNon-small cell lung cancerOrthotopic human lung cancerProtein tyrosine kinase inhibitorEndothelial cellsTumor-associated endothelial cellsHuman lung cancer specimensAdvanced lung cancerSelective protein tyrosine kinase inhibitorCell lung cancerLung cancer patientsOrthotopic mouse modelEndothelial cell tube formationLung cancer specimensHuman lung adenocarcinoma cellsTyrosine kinase inhibitorsSmall molecule inhibitors
2006
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition
Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition. Molecular Cancer Therapeutics 2006, 5: 2685-2695. PMID: 17121915, DOI: 10.1158/1535-7163.mct-06-0142.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorFemaleFibroblastsHumansInsulin-Like Growth Factor Binding Protein 3Lung NeoplasmsMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsMiceMice, NudeNeoplasm MetastasisNIH 3T3 CellsReceptor, IGF Type 1Recombinant ProteinsSignal TransductionUrokinase-Type Plasminogen ActivatorConceptsNon-small cell lung cancerInsulin-like growth factorIGF-independent mechanismsIGFBP-3Recombinant IGFBP-3Expression/activityLung cancerNSCLC cellsMajor IGF-binding proteinProtein 3H1299 cellsLung cancer cell metastasisGrowth factorInvasion of H1299Experimental animal model systemsCell lung cancerIGF-binding proteinsLung cancer metastasisA549 NSCLC cellsMatrix metalloproteinase-2Anti-invasive activityHuman lung fibroblastsCancer cell metastasisAnimal model systemsPlasminogen activator inhibitionTherapeutic options to target angiogenesis in human malignancies
Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opinion On Emerging Drugs 2006, 11: 635-650. PMID: 17064223, DOI: 10.1517/14728214.11.4.635.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHuman malignanciesMonoclonal antibodiesGrowth factorKinase inhibitorsAnti-VEGF inhibitorsGastrointestinal stromal tumorsSolid human malignanciesRenal cell carcinomaBasic fibroblast growth factorRole of VEGFTypes of cancerFibroblast growth factorStromal tumorsTherapeutic optionsCell carcinomaColorectal cancerAntiangiogenic drugsClinical trialsDrug classesPro-angiogenic growth factorsSmall molecule inhibitorsTumor growthTumor angiogenesisMatrix breakdownCombining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Sandler A, Herbst R. Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. Clinical Cancer Research 2006, 12: 4421s-4425s. PMID: 16857821, DOI: 10.1158/1078-0432.ccr-06-0796.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDrug SynergismEpidermal Growth FactorErlotinib HydrochlorideFemaleHumansLung NeoplasmsMaleQuinazolinesVascular Endothelial Growth Factor AConceptsNon-small cell lung cancerPhase II doseStage IIIB/IV non-small cell lung cancerAdvanced non-small cell lung cancerPhase I/II studyEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsRandomized phase II trialVascular endothelial growth factor (VEGF) pathwaySelective epidermal growth factor receptor tyrosine kinase inhibitorEndothelial growth factor pathwayReceptor tyrosine kinase inhibitorsGrowth factorCommon adverse eventsMedian overall survivalPhase II trialPhase III trialsProgression-free survivalSafety of erlotinibCell lung cancerHumanized monoclonal antibodyVascular endothelial growth factorTyrosine kinase inhibitorsEndothelial growth factorGrowth factor pathways
2005
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. Journal Of Clinical Oncology 2005, 23: 5474-5483. PMID: 16027439, DOI: 10.1200/jco.2005.04.192.Peer-Reviewed Original ResearchConceptsAdvanced solid tumorsAG-013736Clinical activityOral receptor tyrosine kinase inhibitorSolid tumorsReceptor tyrosine kinase inhibitorsGrowth factorSingle test dosesMaximum-tolerated dosePhase II doseDose-limiting toxicitySignificant drug interactionsPeak plasma concentrationEndothelial cell growth factorPhase II testingVascular endothelial cell growth factorTyrosine kinase inhibitorsHighest dose levelPlatelet-derived growth factorIndividual PK parametersEffect of foodCell growth factorObserved hypertensionDrug holidayPartial responseCurrent Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy
Isobe T, Herbst RS, Onn A. Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. Seminars In Oncology 2005, 32: 315-328. PMID: 15988686, DOI: 10.1053/j.seminoncol.2005.02.016.Peer-Reviewed Original ResearchMeSH KeywordsAlkyl and Aryl TransferasesAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCyclooxygenase InhibitorsDrug Delivery SystemsErbB ReceptorsFarnesyltranstransferaseHumansLung NeoplasmsMatrix Metalloproteinase InhibitorsProtein Kinase CReceptor, ErbB-2Receptors, Vascular Endothelial Growth FactorRetinoid X ReceptorsConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerLung cancerVascular endothelial growth factorEpidermal growth factor receptorBiological therapyGrowth factorLung cancer patientsCancer-related deathLung cancer progressionClinical study designNew therapeutic strategiesEndothelial growth factorGrowth factor receptorOverall prognosisPatient survivalStandard treatmentCancer patientsConventional chemotherapyFrequent causeRadiation therapyTherapeutic approachesAnticancer arsenalTherapeutic strategies
2004
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer
Sandler AB, Johnson DH, Herbst RS. Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer. Clinical Cancer Research 2004, 10: 4258s-4262s. PMID: 15217970, DOI: 10.1158/1078-0432.ccr-040023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMetastatic non-small cell lung cancerCarboplatin/paclitaxel chemotherapyCell lung cancerVascular endothelial growth factorEndothelial growth factorPaclitaxel chemotherapyLung cancerAdvanced metastatic non-small cell lung cancerStandard carboplatin/paclitaxel chemotherapyPhase I/II studyRecent phase II trialGrowth factorCurrent chemotherapy regimensEastern Cooperative GroupNeo-adjuvant studyNon-squamous histologyRole of bevacizumabNausea/vomitingAddition of bevacizumabPhase II trialPhase III studyTyrosine kinase inhibitor agentsSquamous cell histologySubset of patients
2003
In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor
Yano S, Herbst RS, Sone S. In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor. Methods In Molecular Medicine 2003, 74: 391-398. PMID: 12415710, DOI: 10.1385/1-59259-323-2:391.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCapillary PermeabilityCell DivisionCells, CulturedEndothelial Growth FactorsEndothelium, VascularHumansImmunoglobulin GIn Vitro TechniquesIntercellular Signaling Peptides and ProteinsLymphokinesMaleMiceMice, Inbred C57BLMice, NudeReceptors, Vascular Endothelial Growth FactorRecombinant ProteinsTetrazolium SaltsThiazolesThymidineVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsNon-small cell lung cancerVascular endothelial growth factorLung cancerEarly-stage non-small cell lung cancerCell lung cancerNormal bronchial epitheliumEndothelial growth factorNew blood vesselsBronchial dysplasiaPoor prognosisPrimary tumorLung carcinogenesisMicrovascular densityBronchial epitheliumSolid tumorsBlood vesselsGrowth factorTumorsMetabolic demandsVivo assaysCancerEarly stagesCarcinomaPrognosisHyperplasia
2001
Epidermal growth factor receptor biology (IMC-C225)
Kim E, Khuri F, Herbst R. Epidermal growth factor receptor biology (IMC-C225). Current Opinion In Oncology 2001, 13: 506-513. PMID: 11673692, DOI: 10.1097/00001622-200111000-00014.Peer-Reviewed Original ResearchConceptsIMC-C225Epidermal growth factor receptor biologyMonoclonal antibodiesLigand-linked toxinsOverall clinical outcomeOverall poor prognosisTyrosine kinase inhibitorsTyrosine kinase inhibitionOverexpression of EGFRNovel monoclonal antibodyClinical outcomesPoor prognosisTreatment of cancerRadiation therapySolid tumorsEpithelial cancersTumor proliferationEGFRGrowth factorKinase inhibitorsCancerReceptor biologyAntibodiesKinase inhibitionEGF receptor
1997
Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin
Teicher B, Maehara Y, Kakeh Y, Ara G, Keyes S, Wong J, Herbst R. Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin. International Journal Of Cancer 1997, 71: 49-58. PMID: 9096665, DOI: 10.1002/(sici)1097-0215(19970328)71:1<49::aid-ijc10>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsEMT-6/CDDP tumorTumor cell survivalParent tumorResistant tumorsDrug resistanceAdministration of decorinCell survivalEMT-6/CTXPlasma TGF-beta levelsTGF-beta proteinGranulocyte-macrophage colony-stimulating factorSitu hybridizationTGF-beta levelsVivo drug resistanceHigher plasma levelsTGF-beta mRNATumor-bearing animalsMurine mammary tumorsGrowth factorColony-stimulating factorDrug responseDecorinCytotoxic therapyPlasma levelsTumor levels